Estimation of 24-h aldosterone secretion in the dog using the urine aldosterone:Creatinine ratio

Gardner, Sarah Y.; Atkins, Clarke E.; Rausch, William; DeFrancesco, Teresa C.; Chandler, Donald Walt; Keene, Bruce W.

doi:10.1016/j.jvc.2006.11.001

Cited by 23 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urinary aldosterone concentrations have been used to evaluate the terminal cascade of the RAAS in dogs and the UAldo : C has been validated as an accurate measure of 24‐hours urinary aldosterone secretion in dogs 36, 38. The effect of S/V to decrease aldosterone concentrations is multifactorial.…”

Section: Discussionmentioning

confidence: 99%

“…During each visit on day 0 and day 30, an additional 5 mL of urine were collected either by voiding or cystocentesis. Two and one‐half mL of the first‐morning urine sample (brought by the owner) and 2.5 mL of the urine sample collected at the visit were pooled together36 and centrifuged at 1500 g for 5 minutes. Three milliliter of the supernatant were collected into polypropylene tubes and stored in −80°C until batch analysis.…”

Section: Methodsmentioning

confidence: 99%

“…Three milliliter of the supernatant were collected into polypropylene tubes and stored in −80°C until batch analysis. Urine creatinine concentrations were measured using a standard colorimetric assay and urine aldosterone concentrations were measured contemporaneously from the same urine samples (Aldosterone, Active RIA, Beckman‐Coulter, Brea, California) to calculate the UAldo : C 36. Both tests to determine the urine creatinine and urine aldosterone concentrations were performed by a veterinary diagnostic laboratory (Michigan State University Center for Population and Animal Health, Lansing, Michigan).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease

Newhard

Jung

Winter

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundThe effects of sacubitril/valsartan (S/V) on the renin‐angiotensin‐aldosterone system (RAAS) in dogs with cardiomegaly secondary to myxomatous mitral valve disease (MMVD) are currently unknown.ObjectivesTo determine the pharmacodynamic effects of S/V on the RAAS, natriuretic peptide concentrations, systolic arterial pressure (SAP), tests of renal function, and serum electrolyte concentrations in dogs with cardiomegaly secondary to MMVD.AnimalsThirteen client‐owned dogs weighing 4‐15 kg with American College of Veterinary Internal Medicine (ACVIM) Stage B2 MMVD.MethodsProspective, randomized, double‐blind, placebo‐controlled pilot study of S/V in dogs with ACVIM Stage B2 MMVD.ResultsThirteen dogs were recruited: S/V (n = 7) and placebo (n = 6). The median percentage increase in urinary aldosterone to creatinine ratio (UAldo : C) between day 0 and day 30 was significantly lower in the S/V group (12%; P = .032) as compared with the placebo group (195%). The median percentage decrease of NT‐proBNP concentration from day 0 to day 30 was not statistically different between groups (P = .68). No statistical differences were seen in echocardiographic, thoracic radiographic, SAP, or serum biochemical test results measured at any time point between groups. No adverse events were observed for dogs in either group.Conclusion and Clinical ImportanceSacubitril/valsartan may provide a new pharmaceutical method to effectively inhibit the RAAS in dogs with ACVIM Stage B2 MMVD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease

Newhard

Jung

Winter

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…sodium and potassium intake) are important factors to consider as they result in large intraindividual variations. Population studies of plasma aldosterone concentration may provide worthwhile results, while values for individuals may be less meaningful (Gardner et al, 2007).…”

Section: Aldosterone In Heart Failurementioning

confidence: 99%

Aldosterone receptor antagonists - how cardiovascular actions may explain their beneficial effects in heart failure

Ovaert¹,

Elliott

Bernay³

et al. 2010

Journal of Veterinary Pharmacology and Therapeutics

View full text Add to dashboard Cite

Ovaert, P., Elliott, J., Bernay, F., Guillot, E., Bardon, T. Aldosterone receptor antagonists – how cardiovascular actions may explain their beneficial effects in heart failure. J. vet. Pharmacol. Therap.33, 109–117. Historically, aldosterone receptor antagonists (ARA) have been classified as ‘potassium sparing diuretics’. However, the positive effect of spironolactone, the most extensively studied ARA, on morbidity and mortality observed in humans suffering cardiac insufficiency could not be explained by the renal effect of the drug alone, and a pivotal clinical study has led to extensive research. Many experimental studies have demonstrated that ARA have previously unexpected beneficial effects on the cardiovascular system including reduction in remodelling of the vascular smooth muscle cells and myocytes and improvement of endothelial cell dysfunction in heart failure. These effects improve vascular compliance and slow down the progression of left ventricular dysfunction and end‐organ damage. Furthermore, aldosterone receptor blockade also restores the baroreceptor reflex, improving heart rate variability in heart failure in humans. Some of these effects have been demonstrated in dog models of cardiac disease and so justified further investigation of the potential benefit of ARA in dogs with congestive heart failure (CHF). Positive effects of spironolactone on morbidity and mortality appear to have been seen in studies conducted in dogs suffering from naturally occurring CHF. In addition, eplerenone has been shown to have benefits in canine models of heart failure. The precise mechanisms by which ARA produce these beneficial effects in dogs remain to be determined but this group of drugs clearly provide therapeutic actions out‐with their diuretic effects.

show abstract

“…17 Recently, determination of the spot urine aldosterone to creatinine ratio has been proposed as a simple index of aldosterone excretion, which would allow easier evaluation of the renin-angiotensin-aldosterone system in canine patients. 18 Another indication for SP in dogs is resistance to furosemide treatment. However, it was shown that SP had no diuretic efficacy when combined with acute oral dosing of furosemide in healthy Greyhounds.…”

Section: Discussionmentioning

confidence: 99%

Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs

Jeunesse

Woehrle²,

Schneider³

et al. 2007

Journal of Veterinary Cardiology

View full text Add to dashboard Cite

Estimation of 24-h aldosterone secretion in the dog using the urine aldosterone:Creatinine ratio

Cited by 23 publications

References 32 publications

A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease

A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease

Aldosterone receptor antagonists - how cardiovascular actions may explain their beneficial effects in heart failure

Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs

Contact Info

Product

Resources

About